TW321649B
(en)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0824525B1
(en)
*
|
1995-04-27 |
2001-06-13 |
AstraZeneca AB |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
TR199801530T2
(en)
|
1996-02-13 |
1998-11-23 |
Zeneca Limited |
Quinazoline derivatives as VEGF inhibitors.
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
JP4464466B2
(en)
|
1996-03-05 |
2010-05-19 |
アストラゼネカ・ユーケイ・リミテッド |
4-anilinoquinazoline derivatives
|
PL190489B1
(en)
|
1996-04-12 |
2005-12-30 |
Warner Lambert Co |
Irreversible inhibitors of tyrosine kinases
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
ES2186908T3
(en)
|
1996-07-13 |
2003-05-16 |
Glaxo Group Ltd |
HETEROCICICLES CONDENSED COMPOUNDS AS INHIBITORS OF PPROTEINA-TIROSINA-QUINASAS.
|
EP0927164A1
(en)
|
1996-09-10 |
1999-07-07 |
PHARMACIA & UPJOHN COMPANY |
8-hydroxy-7-substituted quinolines as anti-viral agents
|
NZ334125A
(en)
*
|
1996-09-25 |
2000-10-27 |
Zeneca Ltd |
Quinoline derivatives inhibiting the effect of growth factors such as VEGF
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
WO1998056376A1
(en)
*
|
1997-06-13 |
1998-12-17 |
Sugen, Inc. |
Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
|
ATE368665T1
(en)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800575D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
WO2000010981A1
(en)
*
|
1998-08-21 |
2000-03-02 |
Parker Hughes Institute |
Quinazoline derivatives
|
US6184226B1
(en)
*
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
US7262201B1
(en)
*
|
1998-10-08 |
2007-08-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB9822450D0
(en)
*
|
1998-10-14 |
1998-12-09 |
Smithkline Beecham Plc |
Medicaments
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
AU2437900A
(en)
*
|
1999-01-20 |
2000-08-07 |
Smithkline Beecham Plc |
Piperidinylquinolines as protein tyrosine kinase inhibitors
|
CZ306810B6
(en)
|
1999-02-10 |
2017-07-19 |
Astrazeneca Ab |
The use of a quinazoline derivative as an inhibitor of angiogenesis
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
TWI262914B
(en)
*
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
WO2001004102A1
(en)
*
|
1999-07-07 |
2001-01-18 |
Astrazeneca Uk Limited |
Quinazoline derivatives
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
JP2003504363A
(en)
|
1999-07-09 |
2003-02-04 |
グラクソ グループ リミテッド |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
IL148718A0
(en)
|
1999-09-17 |
2002-09-12 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidines as therapeutic agents
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
UA72946C2
(en)
|
1999-11-05 |
2005-05-16 |
Астразенека Аб |
Quinasoline derivatives as inhibitors of vascular endothelial growth factor (vegf)
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
DE60112268T2
(en)
|
2000-03-06 |
2006-05-24 |
Astrazeneca Ab |
USE OF QUINAZOLIN DERIVATIVES AS INHIBITORS OF ANGIOGENESIS
|
WO2001076630A1
(en)
*
|
2000-04-06 |
2001-10-18 |
Kyowa Hakko Kogyo Co., Ltd. |
Diagnostics and remedies for rheumatoid arthritis
|
UA73993C2
(en)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
|
EP1296973B1
(en)
|
2000-06-24 |
2008-11-05 |
AstraZeneca AB |
Guanidine derivatives of quinazoline for use in the treatment of autoimmune diseases
|
SK18102002A3
(en)
*
|
2000-06-28 |
2003-07-01 |
Astrazeneca Ab |
Substituted quinazoline derivatives, their use and a composition comprising said derivatives
|
CZ2003243A3
(en)
|
2000-07-26 |
2003-09-17 |
Smithkline Beecham P. L. C. |
Aminopiperidine quinolines and their azaisosteric analogs exhibiting antibacterial activity
|
US7371765B2
(en)
|
2000-08-09 |
2008-05-13 |
Astrazeneca Ab |
Quinoline derivatives having VEGF inhibiting activity
|
CZ2003486A3
(en)
|
2000-08-21 |
2003-05-14 |
Astrazeneca Ab |
Quinazoline derivatives, process of their preparation and pharmaceutical preparation in which the derivatives are comprised
|
WO2002018383A2
(en)
|
2000-09-01 |
2002-03-07 |
Chiron Corporation |
Aza heterocyclic derivatives and their therapeutic use
|
KR100732206B1
(en)
|
2000-09-11 |
2007-06-27 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
Quinolinone derivatives as tyrosine kinase inhibitors
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
JP2004511479A
(en)
|
2000-10-13 |
2004-04-15 |
アストラゼネカ アクチボラグ |
Quinazoline derivatives
|
ES2318649T3
(en)
|
2000-10-20 |
2009-05-01 |
EISAI R&D MANAGEMENT CO., LTD. |
PROCEDURE FOR PREPARATION OF DERIVATIVES OF 4-FENOXI QUINOLINAS.
|
WO2002034744A1
(en)
*
|
2000-10-25 |
2002-05-02 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4564713B2
(en)
|
2000-11-01 |
2010-10-20 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
Nitrogen heterocyclic compounds, and methods for making nitrogen heterocyclic compounds and intermediates thereof
|
US7067532B2
(en)
|
2000-11-02 |
2006-06-27 |
Astrazeneca |
Substituted quinolines as antitumor agents
|
US7253184B2
(en)
|
2000-11-02 |
2007-08-07 |
Astrazeneca Ab |
4-Substituted quinolines as antitumor agents
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
AU2002245709A1
(en)
*
|
2001-03-23 |
2002-10-08 |
Bayer Corporation |
Rho-kinase inhibitors
|
AR035791A1
(en)
*
|
2001-03-23 |
2004-07-14 |
Bayer Corp |
COMPOUND N, N-DIHETEROCICLICO OF AMINA, INHIBITOR OF THE RHO-KINASE, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS FOR THE PREPARATION OF THE COMPOUND
|
ATE449763T1
(en)
*
|
2001-04-16 |
2009-12-15 |
Eisai R&D Man Co Ltd |
1H-INDAZOLE COMPOUNDS THAT INHIBIT JNK
|
ES2312557T3
(en)
|
2001-04-19 |
2009-03-01 |
Astrazeneca Ab |
DERIVATIVES OF QUINAZOLINA.
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
KR100810468B1
(en)
*
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
|
EP1444210B1
(en)
*
|
2001-11-03 |
2009-02-18 |
AstraZeneca AB |
Qunazoline derivatives as antitumor agents
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
AU2002361846A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
HU229477B1
(en)
|
2001-12-24 |
2014-01-28 |
Astrazeneca Ab |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
AU2003202263A1
(en)
|
2002-01-10 |
2003-07-30 |
Bayer Healthcare Ag |
Roh-kinase inhibitors
|
CA2473510A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
US6943172B2
(en)
|
2002-01-23 |
2005-09-13 |
Bayer Pharmaceuticals Corporation |
Rho-kinase inhibitors
|
JP4445753B2
(en)
|
2002-01-29 |
2010-04-07 |
グラクソ グループ リミテッド |
Aminopiperidine derivatives
|
WO2003064431A2
(en)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
US7268230B2
(en)
*
|
2002-02-01 |
2007-09-11 |
Astrazeneca Ab |
Quinazoline compounds
|
MXPA04007832A
(en)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aryl ureas with angiogenesis inhibiting activity.
|
TW200302722A
(en)
*
|
2002-02-13 |
2003-08-16 |
Astrazeneca Ab |
Therapeutic agents
|
US7645878B2
(en)
*
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
AU2003281193A1
(en)
|
2002-07-09 |
2004-01-23 |
Astrazeneca Ab |
Quinazoline derivatives for use in the treatment of cancer
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1521747B1
(en)
|
2002-07-15 |
2018-09-05 |
Symphony Evolution, Inc. |
Receptor-type kinase modulators and methods of use
|
AU2003250701A1
(en)
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
WO2004018419A2
(en)
|
2002-08-23 |
2004-03-04 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
DE60318089T2
(en)
|
2002-10-09 |
2008-12-04 |
Critical Outcome Technologies, Inc. |
PROTEIN TYROSINE KINASE INHIBITORS
|
US7622592B2
(en)
*
|
2002-11-01 |
2009-11-24 |
Merck & Co., Inc. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
CN100354278C
(en)
*
|
2002-11-04 |
2007-12-12 |
阿斯利康(瑞典)有限公司 |
Quinazoline derivatives as SRC tyrosine kinase inhibitors
|
PT1562955E
(en)
*
|
2002-11-04 |
2008-05-05 |
Astrazeneca Ab |
Quinazoline derivatives as src tyrosine kinase inhibitors
|
CA2501932C
(en)
|
2002-11-13 |
2014-03-11 |
Chiron Corporation |
Use of benzimidazole quinolinones for treating cancer
|
US7429597B2
(en)
|
2002-12-23 |
2008-09-30 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
|
DE10260730A1
(en)
*
|
2002-12-23 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel substituted nitrogen-containing heterobicyclene, their preparation and their use as pharmaceuticals
|
NZ540698A
(en)
|
2002-12-24 |
2008-05-30 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
GB0307333D0
(en)
*
|
2003-03-29 |
2003-05-07 |
Astrazeneca Ab |
Therapeutic agent
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
CA2526617C
(en)
|
2003-05-20 |
2015-04-28 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318422D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
SI1667991T1
(en)
|
2003-09-16 |
2008-10-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP2210607B1
(en)
|
2003-09-26 |
2011-08-17 |
Exelixis Inc. |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
CN101337930B
(en)
|
2003-11-11 |
2010-09-08 |
卫材R&D管理有限公司 |
Urea derivative preparation process
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
BRPI0418102A
(en)
|
2003-12-23 |
2007-04-27 |
Pfizer |
quinoline derivatives
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
EA011402B1
(en)
|
2004-01-23 |
2009-02-27 |
Эмджен Инк. |
Nitrogen-containing heterocyclic compounds and pharmaceutical use thereof
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
EP1713781B1
(en)
|
2004-02-03 |
2008-11-05 |
AstraZeneca AB |
Quinazoline derivatives
|
US7875624B2
(en)
|
2004-02-20 |
2011-01-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulating and measuring cellular adhesion
|
EP1746999B1
(en)
|
2004-05-06 |
2011-11-16 |
Warner-Lambert Company LLC |
4-phenylamino-quinazolin-6-yl-amides
|
WO2005118572A1
(en)
*
|
2004-06-04 |
2005-12-15 |
Astrazeneca Ab |
Quinazoline derivatives as erbb receptor tyrosine kinases
|
WO2005120509A1
(en)
|
2004-06-04 |
2005-12-22 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
US8969379B2
(en)
|
2004-09-17 |
2015-03-03 |
Eisai R&D Management Co., Ltd. |
Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
|
ATE540935T1
(en)
*
|
2004-10-12 |
2012-01-15 |
Astrazeneca Ab |
CHINAZOLINE DERIVATIVES
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
DE602005026865D1
(en)
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
PYRAZOLOPYRIMIDINE COMPOUNDS AS ANTITUM-MEANS
|
US7358256B2
(en)
|
2005-03-28 |
2008-04-15 |
Bristol-Myers Squibb Company |
ATP competitive kinase inhibitors
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Substituted Amid derivatives & methods of use
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
WO2006124413A2
(en)
|
2005-05-13 |
2006-11-23 |
Novartis Ag |
Methods for treating drug resistant cancer
|
CA2608087C
(en)
|
2005-05-17 |
2013-12-10 |
Gabriel Calvin |
Methods for synthesizing heterocyclic compounds
|
EP2266974A1
(en)
|
2005-05-23 |
2010-12-29 |
Novartis AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-Quinolin-2-one lactic acid salts
|
EP1924568A1
(en)
*
|
2005-07-15 |
2008-05-28 |
Schering Corporation |
Quinazoline derivatives useful in cancer treatment
|
WO2007015578A1
(en)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
WO2007034144A1
(en)
|
2005-09-20 |
2007-03-29 |
Astrazeneca Ab |
4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
|
WO2007095124A2
(en)
|
2006-02-10 |
2007-08-23 |
Transtech Pharma, Inc. |
Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
|
UY30183A1
(en)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
QUINOLINE DERIVATIVES
|
CA2652442C
(en)
|
2006-05-18 |
2014-12-09 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for thyroid cancer
|
KR101472600B1
(en)
|
2006-08-28 |
2014-12-15 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
Antitumor agent for undifferentiated gastric cancer
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
WO2009037343A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Janssen Pharmaceutica Nv |
Inhibitors of the interaction between mdm2 and p53
|
CA2703257C
(en)
|
2007-10-29 |
2013-02-19 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
NZ585357A
(en)
|
2007-10-29 |
2012-02-24 |
Natco Pharma Ltd |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
WO2009060945A1
(en)
|
2007-11-09 |
2009-05-14 |
Eisai R & D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
ME01461B
(en)
|
2008-02-07 |
2014-04-20 |
Boehringer Ingelheim Int |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
NZ589883A
(en)
|
2008-05-13 |
2012-06-29 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy} quinazoline
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
EP2313397B1
(en)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
|
KR20200137052A
(en)
|
2009-01-16 |
2020-12-08 |
엑셀리시스, 인코포레이티드 |
Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
UA108618C2
(en)
|
2009-08-07 |
2015-05-25 |
|
APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
|
CA2772642C
(en)
|
2009-09-03 |
2017-08-29 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
EP2586443B1
(en)
|
2010-06-25 |
2016-03-16 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
CN103140484B
(en)
*
|
2010-07-29 |
2015-04-22 |
默克专利有限公司 |
Cyclic amine azaheterocyclic carboxamides
|
KR20200003933A
(en)
|
2011-03-04 |
2020-01-10 |
뉴젠 세러퓨틱스 인코포레이티드 |
Alkyne substituted quinazoline compound and methods of use
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
ES2705950T3
(en)
|
2011-06-03 |
2019-03-27 |
Eisai R&D Man Co Ltd |
Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
|
CN102942561A
(en)
*
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound
|
CN104755463A
(en)
|
2012-12-21 |
2015-07-01 |
卫材R&D管理有限公司 |
Amorphous form of quinoline derivative, and method for producing same
|
WO2014127214A1
(en)
|
2013-02-15 |
2014-08-21 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
ES2831625T3
(en)
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Therapeutic compounds and their uses
|
CN105102450B
(en)
|
2013-04-04 |
2018-03-09 |
詹森药业有限公司 |
N (base of 2,3 dihydro 1H pyrrolo-es [2,3 b] pyridine 5) 4 quinazoline amine and N (base of 2,3 dihydro 1H indoles 5) 4 quinazolinamine derivatives as PERK inhibitor
|
MX368099B
(en)
|
2013-05-14 |
2019-09-19 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds.
|
AR096654A1
(en)
*
|
2013-06-20 |
2016-01-27 |
Ab Science |
DERIVATIVES OF BENZIMIDAZOL AS SELECTIVE INHIBITORS OF PROTEIN QUINASA
|
AU2014320088B2
(en)
|
2013-09-16 |
2017-06-01 |
Astrazeneca Ab |
Therapeutic polymeric nanoparticles and methods of making and using same
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
JP6426194B2
(en)
|
2013-11-01 |
2018-11-21 |
カラ ファーマシューティカルズ インコーポレイテッド |
Crystalline forms of therapeutic compounds and uses thereof
|
SG11201608110WA
(en)
*
|
2014-04-04 |
2016-10-28 |
Pfizer |
Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
|
JO3783B1
(en)
|
2014-08-28 |
2021-01-31 |
Eisai R&D Man Co Ltd |
Highly pure quinoline derivative and method for producing the same
|
DK3263106T3
(en)
|
2015-02-25 |
2024-01-08 |
Eisai R&D Man Co Ltd |
PROCESS FOR SUPPRESSING BITTERNESS OF QUINOLINE DERIVATIVES
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
CN104725364B
(en)
*
|
2015-03-12 |
2017-09-15 |
江苏省中国科学院植物研究所 |
The amine derivative of 6,7 dimethoxyquinazoline 4, its preparation method and medical usage
|
CN107801379B
(en)
|
2015-06-16 |
2021-05-25 |
卫材R&D管理有限公司 |
Anticancer agent
|
EP3359526A4
(en)
|
2015-10-05 |
2019-04-03 |
The Trustees of Columbia University in the City of New York |
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
CN106045980B
(en)
*
|
2016-06-03 |
2017-11-03 |
江苏开放大学 |
A kind of quinazoline derivant and preparation method thereof
|
EP3509421A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10392399B2
(en)
|
2016-09-08 |
2019-08-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10273227B2
(en)
|
2017-04-27 |
2019-04-30 |
Astrazeneca Ab |
C5-anilinoquinazoline compounds and their use in treating cancer
|
WO2018197643A1
(en)
*
|
2017-04-27 |
2018-11-01 |
Astrazeneca Ab |
Phenoxyquinazoline compounds and their use in treating cancer
|
KR20240017986A
(en)
*
|
2017-09-26 |
2024-02-08 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Compositions and methods for treating cancer
|
FR3080620B1
(en)
*
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES
|